Tag Archives: EVOLUT Low Risk

TCT 2023 | ALIGN AR trial

TCT 2023 | EVOLUT Low Risk: 4-Year Follow-up

TCT 2023 | EVOLUT Low Risk: 4-Year Follow-up

In recent years, there has been a steady increase in the use of transcatheter aortic valve replacement (TAVR) in younger patients, with an average age of 74 years, as observed in US medical records. This trend goes alongside encouraging durability results, as demonstrated in the 10-year NOTION study, where structural valve degeneration (SVD) with first-generation

Top